Glenn's mailing address filed with the SEC is C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER, PA, 22902.
Over the last 6 years, insiders at Verrica Pharmaceuticals Inc have traded over $8,200,904 worth of Verrica Pharmaceuticals Inc stock and bought 11,305,854 units worth $62,586,502 . The most active insiders traders include Advisors Llcperceptive Life..., Paul B Manning y John A Iii Stalfort. On average, Verrica Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $213,456. The most recent stock trade was executed by Christopher G. Hayes on 26 August 2024, trading 35,713 units of VRCA stock currently worth $93,211.
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
Verrica Pharmaceuticals Inc executives and other stock owners filed with the SEC include: